The Prospective Evaluation of Peri-Operative Glucocorticoid Use in the Management of Cervicofacial Infections of Odontogenic Origin
Odontogenic Infection of Jaw (Disorder)
About this trial
This is an interventional treatment trial for Odontogenic Infection of Jaw (Disorder) focused on measuring Glucocorticoid
Eligibility Criteria
Inclusion Criteria: Adult patients, over the age of 18 years old Patients with a cervicofacial infection of odontogenic origin that require hospital admission and surgical intervention under the care of the Oral and Maxillofacial Surgery Department at Health Sciences Centre, and a post-operative course in hospital until such time that the patient is deemed suitable for discharge Exclusion Criteria: Patients in whom consent for treatment of cervicofacial infections of odontogenic origin is not obtained pre-operatively, either by the patient or an appropriate alternative decision maker. Patients at the Health Sciences Centre are required to sign their own consent, or in the case of patients unable to sign their own consent for legal or medical reasons, an alternative decision maker is required to provide consent prior to undergoing treatment under general anesthesia/admission (this includes the administration of steroids at the time of surgical intervention and post-operatively) Patients with pertinent medical history that precludes the use of high-dose steroids, including: known hypersensitivity to steroids, severe immune compromise precluding the use of steroids, poorly controlled Type 1 diabetic patients, systemic fungal infections, latent tuberculosis, herpes simplex keratitis, acute psychosis, Cushing's syndrome, peptic ulcer disease, pregnant patients, breastfeeding mothers, markedly elevated creatinine/significant renal disease Patients with concomitant facial fractures leading to cervicofacial infections Patients with pathologic soft tissue or bony entities leading to cervicofacial infections Patients with cervicofacial infections of non-odontogenic origin (where adequate source control may be unachievable)
Sites / Locations
- University of Manitoba
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Solumedrol 1 Dose
Solumedrol 4 Dose
Patients with an odontogenic cervicofacial infection were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Remainder of management was as per protocol.
Patients with an odontogenic cervicofacial infection were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.